妊娠对系统性红斑狼疮患者疾病复发的影响
基于Hopkins狼疮队列1987—2015年数据,纳入1349例14—45岁女性,采用时变暴露分层Cox模型估计妊娠对复发的影响。妊娠期按PGA定义的复发率升高(HR 1.59,95%CI 1.27~1.96),该效应受羟氯喹使用修饰;继续使用羟氯喹似乎可减轻妊娠期及产后复发风险。
要点
- 妊娠期按PGA定义的复发率升高,HR 1.59(95%CI 1.27~1.96)。
- 未用羟氯喹者妊娠期复发HR 1.83(95%CI 1.34~2.45),使用者HR 1.26(95%CI 0.88~1.69)。
- 产后3个月内未用羟氯喹者复发风险同样升高,使用羟氯喹者未见升高。
核心结论
- 研究支持并扩展了既往发现:妊娠期及产后3个月内复发发生率升高。
- 继续使用羟氯喹似乎可减轻妊娠期及产后复发风险。
研究设计与样本
- 数据来自Hopkins狼疮队列1987—2015年。
- 纳入1349例14—45岁、疾病活动度测量超过1次的女性,其中304例患者共398次妊娠。
- 时变暴露分为妊娠期、产后和非妊娠非产后期;采用分层Cox模型估计HR及bootstrap 95%CI。
主要发现
- 妊娠期按PGA定义的复发率升高,HR 1.59(95%CI 1.27~1.96)。
- 未用羟氯喹者妊娠期较非妊娠非产后期复发HR 1.83(95%CI 1.34~2.45),使用羟氯喹者HR 1.26(95%CI 0.88~1.69)。
- 产后3个月内未用羟氯喹者复发风险同样升高,使用羟氯喹者产后未见升高。
关键数值与推荐
- 复发定义1:PGA较前次访视变化≥1。
- 复发定义2:SELENA-SLEDAI较前次访视变化≥4。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prior studies found conflicting results about whether lupus is likely to flare during or after pregnancy. Using a large cohort of pregnant and non-pregnant women with lupus, we estimated the effect of pregnancy on disease flares in systemic lupus erythematosus. METHODS: Data were collected in the Hopkins Lupus Cohort 1987-2015. Women aged 14-45 years with >1 measurement of disease activity were included. The time-varying exposures were classified as pregnancy, postpartum or non-pregnant/non-postpartum periods. Flares were defined as: (1) change in Physician Global Assessment (PGA)≥1 from previous visit and (2) change in Safety of Estrogens in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)≥4 from previous visit. A stratified Cox model estimated HRs with bootstrap 95% CIs. RESULTS: There were 1349 patients, including 398 pregnancies in 304 patients. There was an increased rate of flare defined by PGA during pregnancy (HR: 1.59; 95% CI 1.27 to 1.96); however, this effect was modified by hydroxychloroquine (HCQ) use, with the HR of flares in pregnancy compared with non-pregnant/non-postpartum periods estimated to be 1.83 (95% CI 1.34 to 2.45) for patients with no HCQ use and 1.26 (95% CI 0.88 to 1.69) for patients with HCQ use. The risk of flare was similarly elevated among non-HCQ users in the 3 months postpartum, but not for women taking HCQ after delivery. CONCLUSIONS: Our study supports and extends previous findings that the incidence of flare is increased during pregnancy and within the 3 months postpartum. Continuing HCQ, however, appeared to mitigate the risk of flare during and after pregnancy.
引用
- Eudy AM, Siega-Riz AM, Engel SM, et al. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis. 2018. PMID: 29463519. doi:10.1136/annrheumdis-2017-212535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。